%PDF-1.6
%
1 0 obj
<<
/Lang (en)
/MarkInfo <<
/Marked true
>>
/Metadata 2 0 R
/Outlines 3 0 R
/PageLayout /OneColumn
/PageMode /UseOutlines
/Pages 4 0 R
/StructTreeRoot 5 0 R
/Type /Catalog
/ViewerPreferences <<
/DisplayDocTitle true
>>
>>
endobj
6 0 obj
<<
/Author (Gemeinsamer Bundesausschuss/Federal Joint Committee \(g-ba.de\))
/Category ()
/Comments ()
/Company ()
/CreationDate (D:20220901112352+02'00')
/Creator <4163726F626174205044464D616B65722032302066FC7220576F7264>
/Keywords <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>
/Manager ()
/ModDate (D:20220902085950+02'00')
/Producer (Adobe PDF Library 20.5.173)
/SourceModified (D:20220825144307)
/Subject (Pharmaceuticals Directive:)
/Title (Resolution)
/_DocHome (1460877555)
>>
endobj
2 0 obj
<<
/Length 5293
/Subtype /XML
/Type /Metadata
>>
stream
2022-09-02T08:59:50+02:00
2022-09-01T11:23:52+02:00
2022-09-02T08:59:50+02:00
Acrobat PDFMaker 20 für Word
uuid:4d4f4cec-8985-41ae-aabd-afc1df919a9f
uuid:5a119326-a516-4422-a68f-c9b063530caf
2
application/pdf
Resolution
Pharmaceuticals Directive:
Gemeinsamer Bundesausschuss/Federal Joint Committee (g-ba.de)
Annex XII – Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a SGB V
Ivacaftor/ Tezacaftor/ Elexacaftor (new therapeutic indication: cystic fibrosis
combination regimen with ivacaftor
6 to 11 years (heterozygous for F508del and other or unknown mutations))
Adobe PDF Library 20.5.173
Annex XII – Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a SGB V
Ivacaftor/ Tezacaftor/ Elexacaftor (new therapeutic indication: cystic fibrosis, combination regimen with ivacaftor, 6 to 11 years (heterozygous for F508del and other or unknown mutations))
D:20220825144307
1460877555
Arzneimittel-Richtlinie: Anlage XII â•fi Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a SGB V
endstream
endobj
3 0 obj
<<
/Count 9
/First 7 0 R
/Last 8 0 R
/Type /Outlines
>>
endobj
4 0 obj
<<
/Count 4
/Kids [9 0 R 10 0 R 11 0 R 12 0 R]
/Type /Pages
>>
endobj
5 0 obj
<<
/K 13 0 R
/ParentTree 14 0 R
/ParentTreeNextKey 8
/RoleMap 15 0 R
/Type /StructTreeRoot
>>
endobj
7 0 obj
<<
/A 16 0 R
/Next 17 0 R
/Parent 3 0 R
/Title (Resolution)
>>
endobj
8 0 obj
<<
/A 18 0 R
/Parent 3 0 R
/Prev 19 0 R
/Title (II. The resolution will enter into force on the day of its publication on the website of the G-BA on 4 August 2022.)
>>
endobj
9 0 obj
<<
/Contents [20 0 R 21 0 R 22 0 R 23 0 R 24 0 R 25 0 R 26 0 R 27 0 R 28 0 R]
/CropBox [0.0 0.0 595.32 841.92]
/MediaBox [0.0 0.0 595.32 841.92]
/Parent 4 0 R
/Resources <<
/Font <<
/TT0 29 0 R
/TT1 30 0 R
/TT2 31 0 R
>>
/XObject <<
/OL1 32 0 R
>>
>>
/Rotate 0
/StructParents 0
/Tabs /S
/Type /Page
>>
endobj
10 0 obj
<<
/Contents [33 0 R 34 0 R]
/CropBox [0.0 0.0 595.32 841.92]
/MediaBox [0.0 0.0 595.32 841.92]
/Parent 4 0 R
/Resources <<
/Font <<
/TT0 29 0 R
/TT1 30 0 R
/TT2 31 0 R
>>
/XObject <<
/OL1 32 0 R
>>
>>
/Rotate 0
/StructParents 1
/Tabs /S
/Type /Page
>>
endobj
11 0 obj
<<
/Contents [35 0 R 36 0 R]
/CropBox [0.0 0.0 595.32 841.92]
/MediaBox [0.0 0.0 595.32 841.92]
/Parent 4 0 R
/Resources <<
/Font <<
/C2_0 37 0 R
/C2_1 38 0 R
/TT0 29 0 R
/TT1 30 0 R
/TT2 31 0 R
>>
/XObject <<
/OL1 32 0 R
>>
>>
/Rotate 0
/StructParents 2
/Tabs /S
/Type /Page
>>
endobj
12 0 obj
<<
/Annots [39 0 R 40 0 R 41 0 R 42 0 R]
/Contents [43 0 R 44 0 R]
/CropBox [0.0 0.0 595.32 841.92]
/MediaBox [0.0 0.0 595.32 841.92]
/Parent 4 0 R
/Resources <<
/Font <<
/TT0 29 0 R
/TT1 30 0 R
/TT2 31 0 R
>>
/XObject <<
/OL1 32 0 R
>>
>>
/Rotate 0
/StructParents 3
/Tabs /S
/Type /Page
>>
endobj
13 0 obj
<<
/K [45 0 R 46 0 R 47 0 R 48 0 R 49 0 R 50 0 R 51 0 R 52 0 R 53 0 R 54 0 R
55 0 R 56 0 R 57 0 R 58 0 R 59 0 R 60 0 R 61 0 R 62 0 R 63 0 R 64 0 R
65 0 R 66 0 R 67 0 R 68 0 R 69 0 R 70 0 R 71 0 R 72 0 R 73 0 R 74 0 R
75 0 R 76 0 R 77 0 R 78 0 R 79 0 R 80 0 R 81 0 R 82 0 R 83 0 R 84 0 R
85 0 R 86 0 R 87 0 R 88 0 R 89 0 R 90 0 R 91 0 R 92 0 R 93 0 R 94 0 R
95 0 R 96 0 R 97 0 R 98 0 R 99 0 R 100 0 R 101 0 R 102 0 R 103 0 R]
/P 5 0 R
/S /Sect
>>
endobj
14 0 obj
<<
/Nums [0 [45 0 R 46 0 R 47 0 R 48 0 R 49 0 R 50 0 R 51 0 R 52 0 R 53 0 R 54 0 R
55 0 R]
1 [56 0 R 57 0 R 58 0 R 59 0 R 60 0 R 61 0 R 62 0 R 63 0 R 64 0 R 65 0 R
66 0 R 67 0 R 68 0 R 69 0 R 70 0 R 71 0 R 72 0 R 73 0 R 74 0 R]
2 [75 0 R 76 0 R 77 0 R 78 0 R 79 0 R 80 0 R null 104 0 R null 105 0 R
null null 106 0 R null 107 0 R null 108 0 R null null 109 0 R
null 110 0 R null 111 0 R null 112 0 R null 113 0 R 114 0 R 115 0 R
null 116 0 R null 117 0 R 118 0 R 119 0 R null 120 0 R null 121 0 R
122 0 R 123 0 R null 124 0 R null 125 0 R 126 0 R 127 0 R null 128 0 R
null 129 0 R null 130 0 R null 131 0 R null 132 0 R null 133 0 R
null 134 0 R null 135 0 R null 136 0 R 82 0 R 83 0 R 84 0 R 85 0 R
86 0 R 87 0 R 88 0 R]
3 [null 137 0 R 89 0 R 90 0 R 91 0 R 92 0 R 93 0 R null 138 0 R null
139 0 R null null 140 0 R null 141 0 R null 142 0 R null 143 0 R
null 144 0 R null 145 0 R null 146 0 R null 147 0 R 148 0 R null
149 0 R null 150 0 R 151 0 R null 152 0 R null 153 0 R 154 0 R null
155 0 R null 156 0 R 157 0 R null 158 0 R null 159 0 R null 160 0 R
null 161 0 R null 162 0 R 163 0 R 95 0 R 96 0 R 97 0 R 98 0 R 99 0 R
164 0 R 99 0 R 100 0 R 101 0 R 102 0 R 103 0 R]
4 137 0 R
5 137 0 R 6 164 0 R 7 164 0 R]
>>
endobj
15 0 obj
<<
/Annotation /Span
/Artifact /P
/Bibliography /BibEntry
/Chart /Figure
/Diagram /Figure
/DropCap /Figure
/Endnote /Note
/Footnote /Note
/InlineShape /Figure
/Outline /Span
/Strikeout /Span
/Subscript /Span
/Superscript /Span
/TextBox /Art
/Underline /Span
>>
endobj
16 0 obj
<<
/D [9 0 R /XYZ 69 743 0.0]
/S /GoTo
>>
endobj
17 0 obj
<<
/A 165 0 R
/Next 166 0 R
/Parent 3 0 R
/Prev 7 0 R
/Title (of the Federal Joint Committee on an Amendment of the Pharmaceuticals Directive:)
>>
endobj
18 0 obj
<<
/D [12 0 R /XYZ 69 325 0.0]
/S /GoTo
>>
endobj
19 0 obj
<<
/A 167 0 R
/Count 4
/First 168 0 R
/Last 169 0 R
/Next 8 0 R
/Parent 3 0 R
/Prev 166 0 R
/Title (I. In Annex XII, the following information shall be added after No. 4 to the information on the benefit assessment of Ivacaftor/ Tezacaftor/ Elexacaftor in accordance with the resolution of 4 August 2022:)
>>
endobj
20 0 obj
<<
/Length 37
/Filter /FlateDecode
>>
stream
x+*23P0bdBr.KB W
endstream
endobj
21 0 obj
<<
/Length 823
/Filter /FlateDecode
>>
stream
HVMo7ϯYID 0
CfI#1@H;8H%dt~8?|<7w?RDYb.TC]rLoO_>iqxO>}v/.46
7ih%D:L>LƼ$#J%a[(, +XffҨ*Ŗ
LUmӟt1%\\1)27b7\iS
8LL DNhb^K,tM*PmH9H,#]O`qDKsۑ% nh# +j)WϡTJe-14L0%ڥtn3`x·Pjf5
JF;d3hAY}K),T7 R@">&@!]5=óK"[虾҆>@ZYڕKOx9o!؍ѲYԭAO]c>Ϙ3@68l1
y== s:E:{#|5wՇ1wPjG:`Z[_KqԲG-xA֢q,d_3%lZrzPDUURu[4Tסu=y]6oz)IŨjxCWcu[fh]%MU>tl`c+$ck؇s;7ZOZZ۱'_p?\ϥB4>1٣RhW ˸
endstream
endobj
22 0 obj
<<
/Length 876
/Filter /FlateDecode
>>
stream
HUInA+1HA@|1OUd;l*i[mևmH;kp^\)b
C%%8a!I_5bw{m:=%ӡ"|pǯ)(h2[҄Qخƣiؙx{yeZHj